{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:07:24Z","timestamp":1755216444510,"version":"3.43.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.yrtph.2025.105857","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T02:47:20Z","timestamp":1747968440000},"page":"105857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rivastigmine as an alternative in physostigmine shortage for anticholinergic toxicity treatment"],"prefix":"10.1016","volume":"162","author":[{"given":"Omid","family":"Mehrpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaneh","family":"Nakhaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yrtph.2025.105857_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15563650.2017.1342828","article-title":"Safety and effectiveness of physostigmine: a 10-year retrospective review","volume":"56","author":"Arens","year":"2018","journal-title":"Clin. Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2025.105857_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.51262\/ejtox.702401","article-title":"A rare situation in childhood: anticholinergic syndrome due to biperiden intoxication","volume":"3","author":"\u00c7elik","year":"2021","journal-title":"Eurasian J. Toxicol."},{"issue":"7","key":"10.1016\/j.yrtph.2025.105857_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/pharmaceutics12070599","article-title":"Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters","volume":"12","author":"Cunha","year":"2020","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.yrtph.2025.105857_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bcp.12839","article-title":"Pharmacological management of anticholinergic delirium - theory, evidence and practice","volume":"81","author":"Dawson","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2025.105857_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3233\/JAD-190626","article-title":"Is combining an anticholinergic with a cholinesterase inhibitor a good strategy for high-level CNS cholinesterase inhibition?","volume":"71","author":"DE","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.yrtph.2025.105857_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1755-5949.2010.00141.x","article-title":"Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease","volume":"16","author":"Emre","year":"2010","journal-title":"CNS Neurosci. Ther."},{"issue":"10","key":"10.1016\/j.yrtph.2025.105857_bib7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/cns.12158","article-title":"A 24\u2010week, randomized, controlled trial of rivastigmine patch 13.3 mg\/24 h versus 4.6 mg\/24 h in severe Alzheimer's dementia","volume":"19","author":"Farlow","year":"2013","journal-title":"CNS Neurosci. Ther."},{"issue":"6","key":"10.1016\/j.yrtph.2025.105857_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cns.12385","article-title":"Evaluating response to high\u2010dose 13.3 mg\/24 h rivastigmine patch in patients with severe Alzheimer's disease","volume":"21","author":"Farlow","year":"2015","journal-title":"CNS Neurosci. Ther."},{"issue":"5","key":"10.1016\/j.yrtph.2025.105857_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1742-1241.2009.02330.x","article-title":"Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease","volume":"64","author":"Grossberg","year":"2010","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.yrtph.2025.105857_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1742-1241.2011.02641.x","article-title":"Dose effects associated with rivastigmine transdermal patch in patients with mild\u2010to\u2010moderate Alzheimer's disease","volume":"65","author":"Grossberg","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"8","key":"10.1016\/j.yrtph.2025.105857_bib11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/15563650.2020.1854281","article-title":"A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome","volume":"59","author":"GS","year":"2021","journal-title":"Clin. Toxicol. (Phila)"},{"issue":"9","key":"10.1016\/j.yrtph.2025.105857_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/15563650.2020.1869757","article-title":"Letter in response to rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication","volume":"59","author":"Hughes","year":"2021","journal-title":"Clin. Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2025.105857_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.ccm.0000551495.67841.67","article-title":"746: cholinergic crisis: rivastigmine to remember","volume":"47","author":"Karnik","year":"2019","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/j.yrtph.2025.105857_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/15563650.2020.1818768","article-title":"Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication","volume":"59","author":"Kernebeek","year":"2021","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.yrtph.2025.105857_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neuro.2015.05.003","article-title":"Is rivastigmine safe as pretreatment against nerve agents poisoning? A pharmacological, physiological and cognitive assessment in healthy young adult volunteers","volume":"49","author":"Lavon","year":"2015","journal-title":"Neurotoxicology"},{"issue":"9","key":"10.1016\/j.yrtph.2025.105857_bib16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/15563650.2020.1870124","article-title":"Comment on Seizure in venlafaxine overdose: a 10-year retrospective review of the California poison control system","volume":"59","author":"Ross","year":"2021","journal-title":"Clin. Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2025.105857_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jen.2019.09.002","article-title":"Physostigmine for antimuscarinic toxicity","volume":"46","author":"Saadi","year":"2020","journal-title":"J. Emerg. Nurs."},{"issue":"1","key":"10.1016\/j.yrtph.2025.105857_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1755-5949.2009.00119.x","article-title":"Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch","volume":"16","author":"Sadowsky","year":"2010","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"10.1016\/j.yrtph.2025.105857_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/bcp.15588","article-title":"Case series profile of olanzapine post\u2010injection delirium\/sedation syndrome","volume":"89","author":"Seebaluck","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2025.105857_bib20","first-page":"141","article-title":"Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice","author":"Seibert","year":"2012","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"5","key":"10.1016\/j.yrtph.2025.105857_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/15563650.2020.1818768","article-title":"Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication","volume":"59","author":"Van Kernebeek","year":"2021","journal-title":"Clin. Toxicol."},{"issue":"9","key":"10.1016\/j.yrtph.2025.105857_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omad096","article-title":"Treatment of pediatric antimuscarinic delirium with oral rivastigmine","author":"Yakey","year":"2023","journal-title":"Oxford Med. Case Rep."},{"issue":"9","key":"10.1016\/j.yrtph.2025.105857_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omad096","article-title":"Treatment of pediatric antimuscarinic delirium with oral rivastigmine","volume":"2023","author":"Yakey","year":"2023","journal-title":"Oxford Med. Case Rep."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002500087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002500087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T10:58:35Z","timestamp":1754305115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027323002500087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"alternative-id":["S027323002500087X"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2025.105857","relation":{},"ISSN":["0273-2300"],"issn-type":[{"type":"print","value":"0273-2300"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivastigmine as an alternative in physostigmine shortage for anticholinergic toxicity treatment","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2025.105857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105857"}}